NRI-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer

This study is currently recruiting participants.
Verified August 2013 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Yolonda L. Colson, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01808417
First received: March 6, 2013
Last updated: August 7, 2013
Last verified: August 2013

March 6, 2013
August 7, 2013
May 2013
May 2015   (final data collection date for primary outcome measure)
  • Feasibility of real-time intraoperative NIR lymphatic mapping [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the feasibility of real-time intraoperative NIR lymphatic mapping with concurrent identification of the sentinel lymph node in esophageal cancer using indocyanine green
  • Number of participants with adverse events [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01808417 on ClinicalTrials.gov Archive Site
Identification of sentinel lymph nodes [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
 
NRI-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer
Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer

This research study is a Phase I clinical trial. Phase I clinical trials test the feasibility and safety of an investigational technique or drug. This study will try to define an appropriate dose of the investigational drug indocyanine green (ICG) in combination with near infrared (NIR) imaging to use for further studies. "Investigational" means that this drug, ICG, is approved by the FDA for other imaging uses, but not for lymphatic mapping using NIR light. Its use for following lymphatic pathways from tumors in the human body is still being studied and research doctors are trying to find out more about it. It also means that the FDA has not approved ICG mapping for your type of cancer.

ICG is a dye and is approved for testing liver function and measuring blood flow from the heart. This drug has been used in studies to map lymphatic pathways in lung cancer and breast cancer and information from those other research studies suggests that this dye may help to identify lymph nodes associated with your esophageal tumor in this research study. ICG can be detected within the body using special near-infrared light cameras. In this research study, the investigators are looking at how easily ICG can get to the first lymph node (called the sentinel lymph node or SLN) associated with your esophageal tumor and whether the investigators can see the path of the ICG and the respective SLN using a near infrared camera.

If you are willing to participate in this study you will be asked to undergo a review of your medical history to confirm that you are eligible. If this review shows that you are eligible you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in the research study.

Your primary surgeon will coordinate the date and time of surgery with you, and the hospital will confirm this schedule.

At the time of surgery, a dose of ICG mixed with normal saline, a solution of salt and water, will be administered in four small injections immediately around your tumor. You will receive approximately half a teaspoon of the normal saline/ICG solution. You will be under general anesthesia. Pictures of the ICG solution will be taken with the NIR camera and the progression of the dye, as it makes its way along the lymphatic channel from the location of your tumor to the SLN, will be monitored. After five to fifteen minutes, the surgeon will continue with your procedure, removing the lymph nodes according to standard or care. The surgeon will discuss this with you ahead of time.

As each lymph node is removed, we will take a picture of it to see if the ICG dye has entered and colored that node.

Following the removal of your lymph nodes, your surgeon will complete the operation and you will continue to be monitored for 30 minutes for any rare but possible side effects (allergic reactions) to the ICG. You will then be removed from the study. With the exception of the administration of the ICG and photography with the NIR camera, there will be no changes from the standard of care.

Following your surgery, we will collect the final pathology results from your procedure. Because we are only looking at determining the feasibility of this technique using NIR imaging, we do not wish to follow you for any period of time following the procedure. If you experience a rare but possible side effect from the ICG, normal saline, or NIR light, we will continue to monitor you until the condition is resolved.

Interventional
Phase 0
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Esophageal Cancer
Procedure: Near Infrared Imaging (NIR) for lymphatic mapping
Experimental: NIR Lymphatic Mapping
NIR Lymphatic Mapping with indocyanine green
Intervention: Procedure: Near Infrared Imaging (NIR) for lymphatic mapping
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
Not Provided
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suspected or confirmed esophageal cancer
  • Deemed an appropriate surgical candidate with consent for esophagectomy and lymphadenectomy or staging lymphadenectomy by their thoracic surgeon

Exclusion Criteria:

  • Patients who choose not to proceed with surgery
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to indocyanine green, including thos patients with a history of iodide or seafood allergy
  • Women who are pregnant or breastfeeding
Both
18 Years and older
No
Contact: Yolonda Colson, MD 6177326648 ycolson@partners.org
United States
 
NCT01808417
12-179
Yes
Yolonda L. Colson, MD, PhD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Not Provided
Principal Investigator: Yolonda Colson, MD, PhD Brigham and Women's Hospital
Dana-Farber Cancer Institute
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP